PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) announced that its management team will host a live fireside chat on Tuesday, April 22, 2025, at 10:00 a.m. EDT to discuss updates on its preclinical cell therapy programs targeting autoimmune diseases and cancer.
The event will cover CNTY-308, a CD19-targeted CAR-iT therapy, CNTY-341, a dual-targeted CD19/CD22 CAR-iT therapy, and the company’s first solid tumor CAR-iT program featuring Nectin-4 CAR and other validated targets. These programs utilize advanced iPSC-derived CD4+/CD8+ ab T cells and are engineered with the proprietary Allo-Evasion™ 5.0 technology, designed to evade T cell, NK cell, and antibody-mediated immunity. The event will also explore the potential for selective iPSC differentiation in non-immune effector cells.
The live event can be accessed on the Investors page of Century’s website at www.centurytx.com. A replay will be available on the website shortly after the event and will remain accessible for at least 30 days.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.